HINT-MI: A Trial for the Earlier Diagnosis of Inferior Wall STEMI Using a Six-lead Handheld EKG Recorder

Sponsor
Ewha Womans University Mokdong Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05777083
Collaborator
(none)
216
1
2
23
9.4

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare the result from the a six-leads handheld electrocardiogram (ECG) recorder (KardiaMobile 6L) with those of the standard 12-leads ECG at the patients of acute inferior wall ST-elevation myocardial infarction (STEMI), then ultimately reduce the time it takes to perform re-through treatment according to the faster diagnosis.

Participants with STEMI who visited the emergency room will be recorded 6-leads ECG using KardiaMobile 6L in addition to the standard 12-lads ECG, which is basically performed for all patients of acute coronary syndrome.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: KardiaMobile 6L
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
216 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
A Trial for the Possibility of Earlier Diagnosis of Inferior Wall ST-elevation Myocardial Infarction Using a Six-lead Handheld EKG Recorder (Kardiamobile 6L)
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Inferior STEMI group

Patients who undergo emergent coronary angiography for ST-elevation myocardial infarction.

Diagnostic Test: KardiaMobile 6L
Before coronary angiography, all participants will contact both fingers on the two probes at the front side of portable 6-leads electrocardiogram recorder (KardiaMobile 6L), and be recorded all six leads by contacting the other side of probe at lower extremities (left hip bone ridge, thigh, knee, lower abdomen, etc.).

Active Comparator: Control group

Patients who undergo elective coronary angiography to differentiate angina symptom. ST-elevation myocardial infarction will be excluded.

Diagnostic Test: KardiaMobile 6L
Before coronary angiography, all participants will contact both fingers on the two probes at the front side of portable 6-leads electrocardiogram recorder (KardiaMobile 6L), and be recorded all six leads by contacting the other side of probe at lower extremities (left hip bone ridge, thigh, knee, lower abdomen, etc.).

Outcome Measures

Primary Outcome Measures

  1. Height (amplitude) of the ST segment of lead II, III and aVF at portable 6-leads electrocardiography (ECG) from KardiaMobile 6L before coronary angiography (CAG) [pre-intervention]

    Height (amplitude) of the ST segment of lead II, III and aVF at portable 6-leads ECG obtained using KardiaMobile 6L between the ER visit and performing emergent CAG (experimental group) or between the admission and elective CAG (control group).

  2. Height (amplitude) of the ST segment of lead II, III and aVF at portable 6-leads ECG from KardiaMobile 6L after CAG [immediately after the intervention (within 30 minutes)]

    Height (amplitude) of the ST segment of lead II, III and aVF at portable 6-leads ECG obtained using KardiaMobile 6L within 30 minutes of the end of the CAG.

  3. Height (amplitude) of the ST segment of lead II, III and aVF at 6-leads ECG from monitoring equipment before CAG [pre-intervention]

    Height (amplitude) of the ST segment of lead II, III and aVF at 6-leads ECG obtained from monitoring equipment at angiographic room between the time of ER visit and performing emergent CAG (experimental group) or between the admission and performing elective CAG (control group).

  4. Height (amplitude) of the ST segment of lead II, III and aVF at 6-leads ECG from monitoring equipment after CAG [immediately after the intervention (within 30 minutes)]

    Height (amplitude) of the ST segment of lead II, III and aVF at 6-leads ECG obtained from monitoring equipment at angiographic room within 30 minutes of the end of the CAG.

  5. Height (amplitude) of the ST segment of lead II, III and aVF at Standard 12-lead ECG before CAG [pre-intervention]

    Height (amplitude) of the ST segment of lead II, III and aVF at Standard 12 lead ECG which is taken between the time of ER visit and performing emergent CAG (experimental group) or between the admission and performing elective CAG (control group).

  6. Height (amplitude) of the ST segment of lead II, III and aVF at Standard 12-lead ECG after CAG [immediately after the intervention (within 30 minutes)]

    Height (amplitude) of the ST segment of lead II, III and aVF at Standard 12 lead ECG which is taken within 30 minutes of the end of the CAG.

Secondary Outcome Measures

  1. Angiographic results [during the procedure]

    Angiographic results of CAG reported by interventional cardiologist who performed CAG. Result is recorded as below; Angiographical Disease Extent 1) normal 2) minimal 3) 1-vessel disease 4) 2-vessel disease 5) 3-vessel disease Left Main Disease : 1) Yes 2) No LAD involvement : 1) Yes 2) No LCX involvement : 1) Yes 2) No RCA involvement : 1) Yes 2) No PCI performing : 1) Yes 2) No Revascularization segment : 1) RCA 2) LAD 3) LCX 4) LM

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Among the patients over 19-year-old, patients of ST-elevation myocardial infarction who visit the emergency room and perform emergency coronary angiography or

  • Among the patients over 19-year-old, patients who visit outpatient clinics and perform elective coronary angiography for evaluating chest pain

Exclusion Criteria:
  • Patients with severe complications of myocardial infarction; cardiogenic shock, respiratory failure and mental change

  • Patients who are unable to agree or disagree a written consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ewha womans university mokdong hospital Yangcheon Seoul Korea, Republic of 07985

Sponsors and Collaborators

  • Ewha Womans University Mokdong Hospital

Investigators

  • Study Chair: In Sook Kang, Ewha Womans University Mokdong Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ewha Womans University Mokdong Hospital
ClinicalTrials.gov Identifier:
NCT05777083
Other Study ID Numbers:
  • HINT-MI
First Posted:
Mar 21, 2023
Last Update Posted:
Mar 21, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ewha Womans University Mokdong Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 21, 2023